Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis?

References

• Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol. 2009;29(10):1702–8.
   PubMed Web of Science ®Google Scholar
• Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68(3):367–72.
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheumatol. 2000;43(1):4–13.
   PubMed Web of Science ®Google Scholar
• Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995;44(1):1–10.
   PubMed Web of Science ®Google Scholar
• Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(Suppl 3):S2.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin AS, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–8.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364(9435):665–74.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the class study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–55.
   PubMed Web of Science ®Google Scholar
• Chan FKL, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–9.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771–81.
   PubMed Web of Science ®Google Scholar
• Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitors. Arthritis Care Res (Hoboken). 2002;47(4):349–55.
   Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22(6):559–70.
   PubMed Web of Science ®Google Scholar
• Bavry AA, Khaliq A, Gong Y, Handberg EM, Cooper-Dehoff RM, Pepine CJ. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med. 2011;124(7):614–20.
   PubMed Web of Science ®Google Scholar
• Olsen A-M, Fosbøl EL, Lindhardsen J, Andersson C, Folke F, Nielsen MB, et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients—a nationwide study. PLoS One. 2013;8(1):e54309.
   PubMed Web of Science ®Google Scholar
• Baigent C, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79.
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–8.
   PubMed Web of Science ®Google Scholar
• Bhosale UA, Quraishi N, Yegnanarayan R, Devasthale D. A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients. J Basic Clin Physiol Pharmacol. 2015;26(1):73.
   PubMedGoogle Scholar
• Chen Y-F, Jobanputra P, Barton P, Bryan S, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2008;12(11):1–278, iii.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes; 2015. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm [last accessed 7 Sept 2015].
   Google Scholar
• Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med. 2006;119(3):255–66.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Dattani ID, Seriolo B, Schneider H, Moore A, Tseng L, et al. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis. Clin Rheumatol. 2011;30(11):1433–46.
   PubMed Web of Science ®Google Scholar
• Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger PM. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021–9.
   PubMed Web of Science ®Google Scholar
• Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, et al. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or = 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther. 2005;27(8):1196–214.
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364(9435):675–84.
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FWA, Chesebro JH, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis. 2007;66(6):764–70.
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Wei L, MacDonald TM. Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis. Eur J Clin Pharmacol. 2013;69(2):133–41.
   PubMed Web of Science ®Google Scholar
• Weaver AL, Messner RP, Storms WW, Polis AB, Najarian DK, Petruschke RA, et al. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. J Clin Rheumatol. 2006;12(1):17–25.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, Najarian DK, Dixon ME, et al. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc. 2004;52(5):666–74.
   PubMed Web of Science ®Google Scholar
• Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003;139(7):539–49.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, Geis GS. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res. 2016;29(6):467–79.
   Web of Science ®Google Scholar
• Williams GW, Hubbard RC, Yu SS, Zhao W, Geis GS. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther. 2001;23(2):213–27.
   PubMed Web of Science ®Google Scholar
• Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology. 2007;46(3):496–507.
   PubMed Web of Science ®Google Scholar
• Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin. 2002;18(2):49–58.
   PubMed Web of Science ®Google Scholar
• Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford). 2002;41(9):1052–61.
   PubMed Web of Science ®Google Scholar
• Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthr Cartil. 2007;15(12):1348–56.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, Reicin AS. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007;66:945–51.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;51(4):549–57.
   PubMed Web of Science ®Google Scholar
• Grifka JK, Zacher J, Brown JP, Seriolo B, Lee A, Moore A, Gimona A. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin Exp Rheumatol. 2004;22(5):589–96.
   PubMed Web of Science ®Google Scholar
• Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage. 2002;10(4):290–6.
   PubMed Web of Science ®Google Scholar
• Cunnington M, Webb D, Qizilbash N, Blum D, Mander A, Funk MJ, Weil J. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf. 2008;17(6):601–8.
   PubMed Web of Science ®Google Scholar
• Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. J Med Assoc Thai. 2009;92(Suppl 6):S19–S26.
   PubMedGoogle Scholar
• de Abajo FJ, Gil MJ, García Poza P, Bryant V, Oliva B, Timoner J, García-Rodríguez LA. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case–control study. Pharmacoepidemiol Drug Saf. 2014;23(11):1128–38.
   PubMed Web of Science ®Google Scholar
• Karha J, Topol EJ. The sad story of Vioxx, and what we should learn from it. Cleve Clin J Med. 2004;71(12):933–9.
   PubMed Web of Science ®Google Scholar
• Geusens P, Alten R, Rovensky J, Sloan VS, Krammer G, Kralidis G, Richardson P. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract. 2004;58(11):1033–41.
   PubMed Web of Science ®Google Scholar
• Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921–8.
   PubMed Web of Science ®Google Scholar
• Bensen W, Weaver A, Espinoza L, Zhao WW, Riley W, Paperiello B, Recker DP. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford). 2002;41(9):1008–16.
   PubMed Web of Science ®Google Scholar
• Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002;3:10.
   PubMedGoogle Scholar
• Williams GW, Kivitz AJ, Brown MT, Verburg KM. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms. Clin Ther. 2006;28(2):204–21.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther. 2004;19(11):1189–98.
   PubMed Web of Science ®Google Scholar
• Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (London, England). 1999;354(9196):2106–11.
   PubMed Web of Science ®Google Scholar
• Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–9.
   PubMed Web of Science ®Google Scholar
• Boers M. Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing? Ann Rheum Dis. 2015;74(5):e33.
   PubMed Web of Science ®Google Scholar
• Grigoriou A, Ibrahim F, Chaabo K, Scott DL, Steer S, Galloway J. Cardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected data. Arthritis Rheumatol. 2014;66:S369–S70.
   PubMed Web of Science ®Google Scholar
• Franklin J, Farragher TM, Lunt M, Camacho EM, Bunn D, Marshall T, Symmons DP. Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis. Ann Rheum Dis. 2010;69(9):1660–4.
   PubMed Web of Science ®Google Scholar
• Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum. 2006;55(4):531–6.
   PubMed Web of Science ®Google Scholar
• Ferraz-Amaro I, Machín S, Carmona L, González-Alvaro I, Díaz-González F. Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice. Reumatol Clin. 2009;5(6):252–8.
   PubMedGoogle Scholar
• Lindhardsen J, Gislason GH, Jacobsen S, Ahlehoff O, Olsen AM, Madsen OR, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;73(8):1515–21.
   PubMed Web of Science ®Google Scholar
• Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case–control study. Arthritis Rheum. 2008;59(8):1090–6.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005;44(5):677–80.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097–104.
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet. 2008;371:270–3.
   PubMed Web of Science ®Google Scholar
• Aljadhey H, Tu W, Hansen RA, Blalock SJ, Brater DC, Murray MD. Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2012;12(1):93.
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–17.
   PubMed Web of Science ®Google Scholar
• van Halm VP, Peters MJL, Voskuyl AE, Boers M, Lems WF, Visser M, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis. 2009;68(9):1395–400.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, et al. Increased risk of chronic kidney disease in rheumatoid arthritis associated with cardiovascular complications—a national population-based cohort study. PLoS One. 2015;10(9):e0136508.
   PubMed Web of Science ®Google Scholar
• Harirforoosh S, Fakhreddin J. Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam. J Appl Toxicol. 2008;28:829–38.
   PubMed Web of Science ®Google Scholar
• del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014;66(2):264–72.
   PubMed Web of Science ®Google Scholar
• Peters MJL, Symmons DPM, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–31.
   PubMed Web of Science ®Google Scholar
• Meara AS, Simon LS. Advice from professional societies: appropriate use of NSAIDs. Pain Med (United States). 2013;14(Suppl 1):S3–S10.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, Mavros P, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology. 2014;54(2):270–7.
   PubMed Web of Science ®Google Scholar
• Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646–56.
   PubMed Web of Science ®Google Scholar
• Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P. Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2005;(1):CD003685.
   Google Scholar
• Tsai WC, Ou TT, Yen JH, Wu CC, Tung YC. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case–control study. PLoS One. 2015;10(5):1–13.
   Web of Science ®Google Scholar
• Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK, Wu DS. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging. 2010;27(10):775–89.
   PubMed Web of Science ®Google Scholar
• Sattelmair J, Pertman J, Ding EL, Kohl HW, Haskell W, Lee I-M. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation. 2011;124(7):789–95.
   PubMed Web of Science ®Google Scholar
• Fiedorowicz J. Depression and cardiovascular disease: an update on how course of illness may influence risk. Curr Psychiatry Rep. 2014;16(10):492.
   PubMed Web of Science ®Google Scholar
• van Breukelen-van der Stoep DF, Klop B, van Zeben D, Hazes JMW, Castro Cabezas M. Cardiovascular risk in rheumatoid arthritis: how to lower the risk? Atherosclerosis. 2013;231(1):163–72.
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez J, Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des. 2007;13(22):2215–27.
   PubMed Web of Science ®Google Scholar
• Wong M, Jiang BY, McNeill K, Farish S, Kirkham B, Chowienczyk P. Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol. 2007;36(4):265–9.
   PubMed Web of Science ®Google Scholar
• Protogerou AD, Sfikakis PP, Stamatelopoulos KS, Papamichael C, Aznaouridis K, Karatzis E, et al. Interrelated modulation of endothelial function in Behcet’s disease by clinical activity and corticosteroid treatment. Arthritis Res Ther. 2007;9(5):R90.
   PubMed Web of Science ®Google Scholar
• Lee TA, Bartle B, Weiss KB. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med. 2007;120:9–16.
   Web of Science ®Google Scholar
• Cheetham TC, Graham DJ, Campen D, Hui R, Spence M, Levy G, Shoor S. Myocardial infarction and its association with the use of nonselective NSAIDs: a nested case–control and time-to-event analysis. Perm J. 2008;12:16–22.
   PubMedGoogle Scholar
• van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RMC. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2009;68:668–73.
   PubMed Web of Science ®Google Scholar
• Bueno H, Bardaji A, Patrignani P, Martin-Merino E, Garcia-Rodriguez LA. Spanish Case-Control Study to Assess N-AACSRI. Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol. 2010;105:1102–6.
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case–control study. Arch Intern Med. 2005;165:978–84.
   PubMed Web of Science ®Google Scholar
• Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906–13.
   PubMed Web of Science ®Google Scholar
• Gislason G, Rasmussen J, Abildstrom S, Schramm TK, Hansen ML, Fosbøl EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169:141–9.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case–control analysis. BMJ. 2005;330:1366.
   PubMed Web of Science ®Google Scholar
• Shau W-Y, Chen H-C, Chen S-T, Chou HW, Chang CH, Kuo CW, Lai MS. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan’s National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord. 2012;12:4.
   PubMed Web of Science ®Google Scholar
• Barthelemy O, Limbourg T, Collet JP, Beygui F, Silvain J, Bellemain-Appaix A, et al. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. Int J Cardiol. 2013;163:266–71.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009;18:1016–25.
   PubMed Web of Science ®Google Scholar
• Roumie CL, Choma NN, Kaltenbach L, Mitchel EF Jr, Arbogast PG, Griffin MR. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009;18:1053–63.
   PubMed Web of Science ®Google Scholar
• Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 2006;113:1950–7.
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D. Increased risk of myo-cardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol. 2006;61:730–7.
   PubMed Web of Science ®Google Scholar
• Helin-Salmivaara A, Virtanen A, Vesalainen R, Grönroos JM, Klaukka T, Idänpään-Heikkilä JE, Huupponen R.. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case–control study from Finland. Eur Heart J. 2006;27:1657–63.
   PubMed Web of Science ®Google Scholar
• Brophy JM, Lévesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007;93:189–94.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol. 2010;69:689–700.
   PubMed Web of Science ®Google Scholar
• Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113:1578–87.
   PubMed Web of Science ®Google Scholar
• Hammad TA, Graham DJ, Staffa JA, Kornegay CJ, Dal Pan GJ. Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf. 2008;17:315–21.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Smeeth L, Persson I, Parkinson J, Leufkens HG. What is the harm-benefit ratio of Cox-2 inhibitors? Int J Epidemiol. 2008;37:405–13.
   PubMed Web of Science ®Google Scholar
• Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162(10):1105.
   PubMed Web of Science ®Google Scholar